DK0960107T3 - 6-Thiosubstituerede paclitaxeler - Google Patents

6-Thiosubstituerede paclitaxeler

Info

Publication number
DK0960107T3
DK0960107T3 DK97954044T DK97954044T DK0960107T3 DK 0960107 T3 DK0960107 T3 DK 0960107T3 DK 97954044 T DK97954044 T DK 97954044T DK 97954044 T DK97954044 T DK 97954044T DK 0960107 T3 DK0960107 T3 DK 0960107T3
Authority
DK
Denmark
Prior art keywords
thiosubstituted
paclitaxels
present
invention concerns
pharmaceutical formulations
Prior art date
Application number
DK97954044T
Other languages
Danish (da)
English (en)
Inventor
Andrew J Staab
John F Kadow
Dolatrai M Vyas
Mark D Wittman
Harold A Mastalerz
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK0960107T3 publication Critical patent/DK0960107T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK97954044T 1996-12-24 1997-12-05 6-Thiosubstituerede paclitaxeler DK0960107T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3341996P 1996-12-24 1996-12-24
US3635197P 1997-01-23 1997-01-23
PCT/US1997/022152 WO1998028288A1 (en) 1996-12-24 1997-12-05 6-thio-substituted paclitaxels

Publications (1)

Publication Number Publication Date
DK0960107T3 true DK0960107T3 (da) 2003-02-10

Family

ID=26709670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97954044T DK0960107T3 (da) 1996-12-24 1997-12-05 6-Thiosubstituerede paclitaxeler

Country Status (11)

Country Link
US (1) US5977386A (cs)
EP (1) EP0960107B1 (cs)
JP (1) JP2001507029A (cs)
AT (1) ATE225341T1 (cs)
AU (1) AU722684B2 (cs)
CA (1) CA2268774A1 (cs)
DE (1) DE69716135T2 (cs)
DK (1) DK0960107T3 (cs)
ES (1) ES2184149T3 (cs)
PT (1) PT960107E (cs)
WO (1) WO1998028288A1 (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6362217B2 (en) 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
DE60131537T2 (de) 2000-06-22 2008-10-23 Nitromed, Inc., Lexington Nitrosierte und nitrosylierte taxane, zubereitungen und methoden der verwendung
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
DK2286795T3 (en) 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
WO2007107305A2 (en) 2006-03-22 2007-09-27 Medigene Ag Treatment of triple receptor negative breast cancer
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP2859916B1 (en) 2008-05-22 2017-11-29 Galera Labs, LLC Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
CN102040570B (zh) * 2009-10-14 2014-07-30 江苏先声药物研究有限公司 硫代紫杉烷类衍生物及其制备方法和用途
US9181343B2 (en) 2012-07-19 2015-11-10 Redwood Bioscience Inc. Antibody specific for CD22 and methods of use thereof
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
KR102813881B1 (ko) 2013-02-15 2025-05-28 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP4592275A3 (en) 2013-11-27 2025-10-29 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
JP6615769B2 (ja) 2014-02-19 2019-12-04 アルデア ファーマシューティカルズ インコーポレイテッド ミトコンドリアアルデヒドデヒドロゲナーゼ2(aldh2)に結合する多環式アミド
CN106459200B (zh) 2014-03-21 2019-12-06 艾伯维公司 抗-egfr抗体及抗体药物偶联物
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
EP3377523A4 (en) 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
IL312621A (en) 2016-06-01 2024-07-01 Servier Ip Uk Ltd Compositions of polyalkylene oxide-asparaginase and methods for their preparation and use
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
WO2017214339A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
KR102434626B1 (ko) 2016-06-08 2022-08-24 애브비 인코포레이티드 항-b7-h3 항체 및 항체 약물 콘쥬게이트
US20200147235A1 (en) 2016-06-08 2020-05-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
BR112019014615A2 (pt) 2017-01-18 2020-06-02 F1 Oncology, Inc. Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
US11629122B2 (en) 2017-05-24 2023-04-18 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
CN110003142A (zh) * 2018-01-04 2019-07-12 深圳福山生物科技有限公司 一种硒氰化合物及其用途
WO2019152661A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
AU2019249221A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating glioblastomas
US12144826B2 (en) 2018-04-06 2024-11-19 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN113692413A (zh) 2019-04-02 2021-11-23 肯乔克蒂生物技术股份有限公司 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法
AU2021214370A1 (en) 2020-01-29 2022-08-18 William Robert ARATHOON Anti-MDR1 antibodies and uses thereof
EP4161650A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
JP7768902B2 (ja) 2020-06-04 2025-11-12 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 Abcg2排出ポンプ-がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
EP4247829A1 (en) 2020-11-20 2023-09-27 R.P. Scherer Technologies, LLC Glycoside dual-cleavage linkers for antibody-drug conjugates
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
JP3304088B2 (ja) * 1991-09-23 2002-07-22 フロリダ・ステイト・ユニバーシティ 10−デスアセトキシタキソール誘導体
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
CA2130578A1 (en) * 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
FR2697019B1 (fr) * 1992-10-15 1994-11-25 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2109861C (en) * 1992-12-04 1999-03-16 Shu-Hui Chen 6,7-modified paclitaxels
WO1994014787A1 (en) * 1992-12-23 1994-07-07 Bristol-Myers Squibb Company Novel sidechain-bearing taxanes and intermediates thereof
MX9308012A (es) * 1992-12-24 1994-08-31 Bristol Myers Squibb Co Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
WO1994020485A1 (en) * 1993-03-05 1994-09-15 Florida State University Process for the preparation of 9-desoxotaxanes
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
CA2161328A1 (en) * 1993-06-11 1994-12-22 Robert C. Kelly Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
CA2192373A1 (en) * 1994-06-09 1995-12-14 Hirofumi Terasawa Deacetoxytaxol derivative
AU2814595A (en) * 1994-06-28 1996-01-25 Pharmacia & Upjohn Company 7-ether-taxol analogs, antineoplastic use and pharmaceutical compositions containing them
CA2195844C (en) * 1994-07-26 2001-10-09 Ezio Bombardelli Semi-synthetic taxanes with anti-tumoural activity

Also Published As

Publication number Publication date
AU5792298A (en) 1998-07-17
AU722684B2 (en) 2000-08-10
PT960107E (pt) 2003-02-28
EP0960107A4 (cs) 1999-12-01
DE69716135D1 (en) 2002-11-07
WO1998028288A1 (en) 1998-07-02
DE69716135T2 (de) 2003-06-05
US5977386A (en) 1999-11-02
JP2001507029A (ja) 2001-05-29
ATE225341T1 (de) 2002-10-15
EP0960107B1 (en) 2002-10-02
CA2268774A1 (en) 1998-07-02
ES2184149T3 (es) 2003-04-01
EP0960107A1 (en) 1999-12-01

Similar Documents

Publication Publication Date Title
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
FI943749A0 (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ATE231872T1 (de) Thiazolopyrimidinderivate
ID23374A (id) Halogenopirimidin
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
MX9601994A (es) Profarmacos de derivados de paclitaxel.
SE9904377D0 (sv) Pharmaceutical combinations
SE9802937D0 (sv) Novel compounds
CA2152771A1 (en) 7-o-ethers of taxane derivatives
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
AU4558201A (en) Taxane anticancer agents
DE50004023D1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
ECSP003536A (es) Derivados de rufomicina utiles como antibioticos